1) Warner TD, Mitchell JA. Cyclooxygenases:new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18(7):790-804.
2) Gallus AS. Antiplatelet drugs:clinical pharmacology and therapeutic use. Drugs 1979;18(6):439-77.
3) Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy:An American College of Chest Physicians Clinical Practice Guideline. Chest 2022;162(5):e207-43. doi:10.1016/j.chest.2022.07.025.
4) Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017;390(10094):613-24.
5) Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper Allergy 2019;74(1):28-39.
6) Beebe HG et al. Cilostazol for intermittent claudication:a randomized, placebo-controlled, double-blind clinical trial. Circulation 1999;100:1564-9.
7) Oduah EI, Linhardt RJ, Sharfstein ST. Heparin:past, present, and future. Pharmaceuticals (Basel) 2016;9(3):38. doi:10.3390/ph9030038.
8) Shuster TA, Silliman WR, Coats RD, et al. Heparin-induced thrombocytopenia:twenty-nine years later. J Vasc Surg 2003;38(6):1316-22.
9) Patel S, Singh R, Preuss CV, et al. Warfarin. [Updated 2024 Oct 5]. In:StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing;2025.
10) January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019;140(2):e125-e51. doi:10.1161/CIR.0000000000000665.
11) Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021;23(10):1612-76.
